Bank of America
ATRA icon

Bank of America’s Atara Biotherapeutics ATRA Stock Holding History

Bank of America’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,716
Closed -$3.41M – 7252
2018
Q2 		$3.41M Buy
+3,716
New +$3.99M ﹤0.01% 3512

Other funds holding ATRA

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America's ATRA Position: Q1 2026 in Review

Bank of America sold out of Atara Biotherapeutics (ATRA) in Q1 2026, closing a stake of 10,387 shares — an estimated $188K sold.

Bank of America first reported a position in ATRA in Q1 2015 and held it in 44 quarters. The position peaked at $7.49M in Q1 2019. 33 funds tracked by Wall St. Rank hold ATRA as of Q1 2026.

  • Bank of America reported no remaining Atara Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 10,387 Atara Biotherapeutics shares in Q1 2026, an estimated $188K.
  • Bank of America first reported a position in Atara Biotherapeutics in Q1 2015 and held it in 44 quarters.
  • Bank of America's Atara Biotherapeutics position peaked at $7.49M in Q1 2019.
  • 33 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.